Empowering Progress: Teplizumab's FDA Approval and Mechanism of Action in Delaying T1D Progression

In this discussion, a panel of diabetes management experts examines the groundbreaking potential of teplizumab, the first FDA-approved therapy of its kind, in delaying the onset of T1D stage progression. They delve into its unique mechanism of action and explore its pivotal role in early intervention strategies.

EP: 1.The Landscape of Diabetes: Unveiling Geographical Disparities and the Role of Prediabetes

EP: 2.Deciphering Diabetes Onset: The Crucial Role of B Cells and Diagnosis Considerations

EP: 3.Navigating the Burden of Diabetes: Screening Recommendations and Insights from Real-Life Experiences

EP: 4.Strategies to Prolong T1D Stage Progression: Impact of Diabetes Ketoacidosis and Potential for Extending Insulin Independence

EP: 5.Type 1 Diabetes Antibody Screening: Keys for Early Intervention and Risk Determination

Now Viewing

EP: 6.Empowering Progress: Teplizumab's FDA Approval and Mechanism of Action in Delaying T1D Progression

EP: 7.Navigating Teplizumab: Dosing, Infusion Process, and Patient Experience in Delaying Late Onset Diabetes

EP: 8.Key Takeaways and Clinical Pearls for the Utilization of Teplizumab

Recent Videos